Efinaconazole

• UNSPSC Description:

  Efinaconazole (KP-103) is a triazole antifungal agent and againsts T. mentagrophytes SM-110 and C. albicans ATCC 10231 with MICs of 0.0039 μg/mL and 0.00098 μg/mL, respectively[1]. Efinaconazole has a potent in vitro activity against fungal pathogens including dermatophytes, Candida and Malassezia species[1].

• Target Antigen:

  Fungal

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/Efinaconazole.html

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  C[C@@H](N1CCC(CC1)=C)[C@@](O)(C2=CC=C(F)C=C2F)CN3N=CN=C3

• Molecular Weight:

  348.39

• References & Citations:

  [1]Tatsumi Y, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May;57(5):2405-9.|[2]Tatsum Y, et al. KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs. Microbiol Immunol. 2002;46(7):425-32.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  164650-44-6